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A B S T R A C T
Drug resistance and off-organ toxicity remain unsolved issues in chemotherapy of advanced-stage melanoma
patients. Thus, the creation of new molecular conjugates able to combine a selective accumulation, high ability
of internalization and signaling pathway inhibition, are highly requested. Recently, we reported a new class of
molecular conjugates, compounds 1–3, where the anti-αVβ3 integrin peptidomimetic c(AmpRGD), which is a
selective ligand for αVβ3 integrin, was covalently bound to the tyrosine kinase inhibitor sunitinib. Here, we
report that these c(AmpRGD)-sunitinib conjugates and, in particular, compound 3, are selectively internalized by
human melanoma cells through αVβ3 receptor-mediated endocytosis. Compound 3 is more effective than su-
nitinib in reducing in vitro melanoma cells proliferation, cloning efficiency, migration, and invasion. More in-
terestingly, compound 3 is able to significantly reduce the growth of xenografted melanoma tumor developed in
immune-compromised mice, more efficiently than an equimolar dose of sunitinib. Indeed, its targeting ability
was demonstrated by the selective localization at the tumor level with respect to healthy tissues. Thus, c
(AmpRGD)-sunitinib conjugates such as compound 3 could serve as intriguing multiple-target agents to selec-
tively reach melanoma cells and interfere with the progression of the disease.
1. Introduction
Melanoma is one of the most aggressive forms of skin cancer diag-
nosed in people, especially those aged 55–64 years. In the past few
decades, the global incidence of melanoma has continuously increased
and it is expected to grow further in the next years, making melanoma a
serious threat to public health [1–4]. Cancer stage at diagnosis de-
termines treatment options and dictates the length of patient survival.
Thus, for localized melanoma lesions (covering about 83% of all cases)
surgery represents the conventional and most effective treatment, re-
sulting in more than 98% survival over 5-years, while advanced-stage
unresectable or metastatic melanoma involving metastases to regional
or distant lymph nodes and/or other sites is generally associated with
poor prognosis and short-term survival [5,6].
Before 2011, metastatic melanoma was considered an almost in-
curable disease, and standard-of-care treatment met only modest clin-
ical benefit by the use of untargeted chemotherapy (dacarbazine) and/
or untargeted immunotherapy (interferon and interleukin cytokines).
The median overall survival obtained was of 9 months and substantial
toxicity was often recorded [7,8]. In-depth, decade-long research into
the genomics of cancer and underpinnings of the immune response
against cancer changed the shape of the frontline treatment of advanced
stage melanomas, with about ten new therapeutic agents having been
approved since 2011 by FDA and homologous agencies for the effective
treatment of metastatic melanoma [9,10].
In particular, the discovery that about half of all melanomas harbor
BRAF mutations, with the most common oncogenic event involving the
V600E mutation in BRAF protein, paved the way to the medicinal
chemistry-driven generation of molecularly targeted small molecules,
such as vemurafenib and dabrafenib, as potent and specific inhibitors of
V600-mutated BRAF [11–16]. Soon after, the appreciation that BRAF
signaling is dependent on downstream activation of MEK1/2, and the
need of overcoming mechanisms of resistance to BRAF inhibitors, led to
the development of small molecule MEK-inhibitors trametinib and
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cobimetinib, approved as monotherapy or, better, in combination with
BRAF inhibitors.
Concurrently, the introduction of immunotherapeutic approaches
using targeted immune checkpoint inhibitors, such as monoclonal an-
tibodies ipilimumab or nivolumab, has demonstrated substantial im-
provement in survival in patients with metastatic disease to at least two
years [17,18].
Despite progress in the clinical management of advanced-stage
melanoma with different treatment options available, mainly based on
consideration of patient-specific features (presence of genetic mod-
ifications, kinetics of melanoma, performance status, comorbidities,
baseline immune recognition, etc.), many concerns still exist dealing
with the observed overall toxicity [19,20], the effective dosing regi-
mens and, above all, the insurgence of resistance mechanisms leading
to tumor relapse and progression to a metastatic disease with incredibly
aggressive features [21].
Given the involvement of multiple, yet strictly related biological
targets and signaling cascades in the metastatic melanoma disease, the
combination therapy has become the standard-of-care treatment, in
both small molecule-based (e.g. vemurafenib + cobinetinib in
BRAFV600E/K-mutant disease) and antibody-based therapies (e.g. ipili-
mumab + nivolumab), with the primary goal to improve clinical
benefit while overcoming the insurgence of drug resistance and com-
pensating mechanisms often observed using targeted monotherapy.
In these cases, however, off-organ (and possible synergistic) toxicity
remains a still unsolved issue, mainly due to the fact that molecularly-
targeted compounds may be cell-unselective, at least when the biological
target is located inside cells. On the other hand, large-size drugs such as
antibodies selectively addressing extracellular biological targets are not
amenable to target intracellular proteins.
The creation of new molecular conjugates which combine in a sole
chemical entity, i) the capability of accumulating in melanoma cells in a
target-selective manner by recognition of specific surface-exposed re-
ceptors, ii) the ability to enter cells, possibly via receptor-mediated
endocytosis, iii) the capacity to modulate key intracellular targets and
signaling pathways, is an appealing approach toward enhanced drug
efficacy at a lowered drug dosage with an increased safety window
[22,23].
Recently, we reported a new class of molecular conjugates, com-
pounds 1–3, where the anti-αVβ3 integrin peptidomimetic c(AmpRGD)
[24–28] was connected to the antiangiogenic and antitumor multi-
kinase inhibitor sunitinib through robust linkers (Fig. 1). The rationale
behind this work was that the c(AmpRGD) portion would have selec-
tively directed the conjugates toward αVβ3-integrin overexpressing cells
(including activated endothelial, melanoma, ovarian, pancreatic, cer-
vical and breast carcinoma, glioblastoma cells) [29], while the sunitinib
moiety would have exerted its anti-angiogenic properties through its
proven ability to inhibit key intracellular tyrosine kinases including
tumor angiogenesis-related VEGFR-2 receptor [30–33]. We demon-
strated, using both in vitro and in vivo protocols, that the robust che-
mical association and co-localization of the two modules – c(AmpRGD)
and sunitinib - increased the capacity to interfere with the synergetic
interactions that follow the crosstalk between the αVβ3 integrin re-
ceptor and VEGFR, thus impairing tumor-associated angiogenesis [28].
Based on the above considerations, we wondered whether these
three conjugates 1–3 could serve as intriguing multiple-target agents to
selectively reach melanoma cells and interfere with the progression of
metastatic melanoma.
In this work, the effect of these different c(AmpRGD)-sunitinib
chemotypes – compounds 1–3 – on a preclinical model of advanced
human melanoma cells has been evaluated. In addition, rationalization
of the observed cell-selective effects has been proposed, based on the
multi-targeting activity of these molecular conjugates as both RTK in-
hibitors and αVβ3 antagonists. We found that, among these c-AmpRGD-
sunitinib conjugates, compound 3, i) is selectively internalized by
human melanoma cells through αVβ3 receptor-mediated endocytosis, ii)
it is more effective than sunitinib in reducing in vitro melanoma cells
proliferation, cloning efficiency, migration and invasion, and iii) it is
able to significantly reduce growth of xenografted melanoma tumor
developed in immune-compromised mice, more efficiently than an
equimolar dose of sunitinib.
2. Materials & methods
2.1. Synthesis
The molecular conjugates 1–3 and the reference compound c
(AmpRGD)-NH2 (4) (Fig. 1) were prepared according to the procedure
reported in Ref. [28]. The sunitinib reference (as sunitinib malate salt)
was purchased by LC Laboratories (USA) with a purity of> 99%.
2.2. pKa determination
The pKa values of sunitinib and compounds 1–3were determined by
the potentiometric pH-metric method employing a Sirius T3 instrument
(Sirius Analytical Ltd, Forrest Row, UK). The detailed experimental
procedure is reported in the Supporting Information [34,35].
2.3. Cell cultures
The human melanoma cell line (M21), human prostate carcinoma
cell line (PC3), and human erythroleukemia cell line K562 were pur-
chased from the American Type Culture Collection (ATCC, Rockville,
MD). M21 and PC3 were grown in Dulbecco's modified Eagle medium,
containing 4500mg/L glucose (DMEM 4500, GIBCO) supplemented
with 10% fetal calf serum (FCS) at 37 °C in a humidified incubator
containing 10% CO2. 5.0× 105 melanoma cells or prostate carcinoma
cells were seeded in 100mm Sarstedt dishes and propagated every 3
days by incubation with a trypsin–EDTA solution. The human ery-
throleukemia cell line K562 was maintained at 37 °C in Iscove's
Modified Dulbecco's Medium (IMDM, GIBCO) supplemented with 10%
FCS in T25 culture flasks (Sarstedt) in a humidified incubator with 5%
CO2. When cultures reached a cell density between 1×105 and
1×106 cells/mL, cells were resuspended in warm fresh media at a
volume to yield a density of 2×105 cells/mL. M21, PC3, and K562
cultures were periodically monitored for mycoplasma contamination
using Chen's fluorochrome test [36].
The expression levels of αVβ3 integrin receptor on M21, PC3, and
K562 cell lines were confirmed by flow cytometric analysis [37,38].
2.4. Inhibition of cell adhesion to vitronectin
96 wells plates were coated with vitronectin (10 μg/mL) (V8379
Sigma) by overnight incubation at 4 °C. Plates were washed with
Phosphate Buffered Saline (PBS) solution and then incubated at 37 °C
for 1 h with PBS containing 1% Bovine Serum Albumin (BSA). M21 cells
were washed by centrifugation with PBS, counted and suspended in
serum-free medium at 0.6×106 cells/mL. Melanoma cell suspensions
were exposed to different amounts of the compounds 1–4 (final con-
centration ranged from 30 μM to 10 nM), while prostate carcinoma
(PC3) and erythroleukemia (K562) cells were exposed to different
concentrations of c(AmpRGD)-NH2 (4). A pre-incubation at 37 °C for
30min was performed to allow the ligand-receptor equilibrium to be
reached. Assays were performed in the presence of 2mmol/L MnCl2.
Cells were then plated on VN substrata (5–6×104 cells/well) and in-
cubated at 37 °C for 1 h. Plates were washed with PBS to remove the
non-adherent cells, and 200 μL of 0.5% crystal violet solution in 20%
methanol were added. After 2 h of incubation at 4 °C, plates were ex-
amined at 540 nm in a counter ELX800 (Bio TEK Instruments).
Experiments were conducted in triplicate and repeated at least three
times. The values are expressed as % inhibition ± SEM of cell adhesion
relative to untreated cells.
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2.5. Clonogenic assay
M21 cells were exposed to different treatments for 24 h and then
seeded at low density (200 cells in 60mm diameter Petri dishes) in
growth medium supplemented with 10% FCS. Cultures were grown for
14 days at 37 °C in a humidified incubator. Growth medium was
changed every 3–4 days. After 2 weeks, the clones were fixed with 4%
formaldehyde and stained with 0.1% crystal violet. In some experi-
ments, M21 cells were exposed for 6 days to different treatments (every
other day) and then seeded at low density in growth medium supple-
mented with 10% FCS. Cultures were grown for 14 days at 37 °C in a
humidified incubator and treated every other day with different treat-
ments and the medium was changed. After 2 weeks, the clones were
fixed with 4% formaldehyde and stained with 0.1% crystal violet. Cell
clones with diameter> 0.5 mm were counted under an optical micro-
scope (10×magnification) and the surviving factor (SF) was calculated
on the basis of the following formulas: cloning efficiency (CE) (%) =
(number of clones formed from untreated cells/number of untreated
cells inoculated)× 100%; surviving factor (SF): (number of clones from
treated cells)/(treated cells seeded×CE) [39]. Proliferation and clo-
nogenic assays were carried out in triplicate and repeated a minimum
of 3 times independently.
2.6. Evaluation of cell internalization of sunitinib and compounds 1–3
Internalization of sunitinib was determined by taking advantage of
the fluorescent emission of sunitinib by means of a cytofluorimetric
assay and immunofluorescence analysis. Briefly, M21 cells were seeded
in standard medium (2× 106 cells/100mm Petri dishes) and after 24 h
adhesion cells were exposed to sunitinib or compounds 1–3 at 1 μM
concentration. After 24 h, cells were gently detached using Accutase
(Lonza) and the fluorescence associated with different cell populations
was evaluated using the FITC channel of the FACSCanto BD instrument.
Untreated cells were used as negative control. For cell selective inter-
nalization experiments 1×106 M21 human melanoma cells were
seeded in complete medium in 60mm dishes and, after 3 h of adhesion,
1× 106 K562 erythroleukemia cells were stratified on M21 cell
monolayers in 1:1 ratio. M21, K562, and M21:K562 cell cultures were
exposed to different treatments with sunitinib or compounds 1–3 at
1 μM concentration for 24 h. After incubation, adherent and non-ad-
herent cells were recovered and washed in PBS, and incubated for 1 h at
4 °C in the presence of anti-αVβ3 monoclonal antibody (1 μg/50 μL)
(clone LM609, Millipore). Cells were then washed and incubated for
1 h at 4 °C with a specific secondary antibody, goat antimouse IgG
conjugated with Cy5 (AbCam) for cytofluorimetric analysis.
For immunofluorescence assay M21 cells (2× 105 cells) were
seeded on vitronectin-coated (2 μg/mL) 25-mm cover glasses, at the
bottom of 60mm dishes, in complete medium, and allowed to grow for
24 h. Cells were successively exposed to different compounds (1 μM) for
24 h. At the end of the incubation, cells were fixed for 20min in 4%
paraformaldehyde. For displacement experiments, M21 cells were ex-
posed to 10 μM concentration of reference compound 4 (2 h) before
treatment with compound 3 at 1 μM concentration for 24 h.
In some experiments (localization), cells were permeabilized with
0.1% Triton X-100 solution in PBS and incubated in blocking solution
(PBS supplemented with 4% BSA and 1% horse serum) and then in-
cubated overnight at 4 °C with the anti-Rab7 antibody (Santa Cruz sc-
376362). Cells were washed and then incubated for 1 h using 1:100
goat anti-rabbit IgG-Cy3. Cell nuclei were counterstained with DAPI
(4′,6-diamidino-2-phenylindole; Life Technologies) (1 μg/mL for
10min). Following two washes in PBS, coverslips were mounted with
1:1 PBS:Glycerol on glass slides and the cells were observed with an
inverted confocal Nikon Eclipse TE2000 microscope equipped with a
960S-Fluor oil immersion lens (FITC filter for sunitinib, Cy3 filter for
Rab-7, DAPI filter for nuclear stain) [40]. A single composite image was
obtained by superimposition of 6 optical sections for each sample ob-
served.
Fig. 1. Molecular structures of c(AmpRGD)-sunitinib conjugates 1–3, antiangiogenic drug sunitinib, and c(AmpRGD)-NH2 4.
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2.7. Western blot assay
M21 cells were exposed for 24 h to serum-free medium for starva-
tion. Next, 1 μM concentration of different compounds was added to
cell monolayers. After 1 h incubation, media were rapidly removed and
cell monolayers were exposed to (100 μL/p100 diameter dishes) RIPA
lysis buffer (50mM Tris pH 7.4, 150mM NaCl, 1% Triton X-100, 1%
sodium deoxycholate, 0.1% SDS, 5mM EDTA) and proteinase inhibitor
cocktail (Roche, Mannheim, Germany) for 30min in ice. Lysates were
then centrifuged at 14,000 r.p.m. for 20min and the supernatants were
collected and stored at −80 °C. Protein content was quantified by the
Bradford method (Bio-Rad, Hercules, CA). Fifty to 60 μg of total pro-
teins were denaturated at 90 °C for 5min in Laemmli buffer and sepa-
rated on Bolt® Bis-Tris Plus gels 4–12% precast polyacrylamide gels
(Life Technologies, Monza, Italy). Fractionated proteins were trans-
ferred from the gel to a PVDF nitrocellulose membrane using the iBlot 2
system (Life Technologies, Monza, Italy). Membranes were blocked for
1 h, at room temperature, with Odyssey blocking buffer (Dasit Science,
Cornaredo, MI, Italy). Subsequently, the membranes were probed at
4 °C overnight with appropriate primary antibodies diluted in a solution
of 1:1 Odyssey blocking buffer/T-PBS buffer, washed four times with
PBS-Tween 0.1% solution, and probed with the secondary IRDye anti-
bodies according to the manufacturer's instructions. The protein bands
were analyzed by the Odyssey Infrared Imaging System (Lycor
Bioscience) using software for protein quantification. The primary an-
tibodies were: rabbit anti-pERK (1:1000, #4370 Cell Signaling
Technology), rabbit anti-ERK (1:1000, #4695 Cell Signaling
Technology), rabbit anti-caspase 3 (Bethyl Lab Inc. A303-657A) which
recognizes full length protein, while mouse anti-α tubulin monoclonal
antibody (1:2000, Sigma, Saint Louis, MO, USA) was used to assess
equal amount of protein loaded in each lane.
2.8. Cell proliferation assay
M21 human melanoma cells were seeded on 6-well plates at
5× 104 cells/well. After 4 h adhesion in complete medium, cells were
exposed to compound 4, sunitinib, and their combination or to com-
pounds 1–3 at 1 μM concentration. After 24 h, 48 h, and 72 h, cell
numbers and cell viability were determined using trypan blue exclusion
assay. In some experiments, the effect of different treatments on the
proliferation of human prostate carcinoma cells (PC3) was determined.
Images of growing cultures were taken at different time points.
2.9. Wound healing of M21 human melanoma cells exposed to sunitinib-
conjugated compounds
Cell migration was evaluated by an in vitro wound healing assay as
previously described [41]. M21 human melanoma cells were grown at
80–90% confluence in 35mm dishes; the cell layer was wounded with a
sterile 200 μL pipette tip and tumor cells were grown in the presence of
compound 4, sunitinib, their combination or compounds 1–3, in stan-
dard media for 24 h. The wound was observed after 24 h and photo-
graphed using phase contrast microscopy.
2.10. Invasiveness of M21 human melanoma cells exposed to sunitinib-
conjugated compounds
Invasiveness of M21 human melanoma cells was determined in vitro
on Matrigel-precoated polycarbonate filters, with 8 μm pore size,
6.5 mm diameter, 12.5 μg Matrigel/filter, mounted in Boyden's cham-
bers as previously described [41]. M21 human melanoma cells were
grown in the presence of compound 4, sunitinib, their combination or
compounds 1–3 in standard media for 24 h. After incubation,
5× 104 cells (200 μL, in serum-free medium) were seeded in the upper
compartment and incubated for 24 h at 37 °C in 10% CO2 in air. In the
lower chamber, complete medium was added as chemoattractant. After
incubation, the inserts were removed and the non-invading cells on the
upper surface were wiped off mechanically with a cotton swab and the
membranes were fixed overnight in ice-cold methanol. Cells on the
lower side of the membranes were then stained using the Diff-Quick kit
(BD Biosciences) and photographs of randomly chosen fields were
taken.
2.11. Xenograft experiments
All experimental procedures involving animals were performed in
accordance with the Italian Guidelines and approved by the ethical
committee of Animal Welfare Office of Italian Work Ministry. A total of
24 female SCID bg/bg mice aged 6–8 weeks (Charles River Laboratories
International, Lecco, Italy) were fed with a regular chow diet (Harlan
Laboratories, Indianapolis, US) and water ad libitum. Human mela-
noma cells were harvested by trypsinization, washed twice in PBS, and
then suspended in PBS:Matrigel solution (1:1) at 3.5× 106 cells per mL;
0.2 mL of cell suspension was injected subcutaneously into the right
flank of mice (six animals per group). After 14 days, mice were ran-
domized into treatment groups when tumor volumes reached
120–150mm3 and i.p. daily treated with vehicle (PBS), with 10mg/kg
dose of sunitinib malate [42], 20mg/kg dose of compound 1 or with
40mg/kg dose of compound 3, to reach an equimolar concentration of
sunitinib. Mice were monitored daily and tumor size was measured
every 2 days by a caliper, and tumor volumes were determined by the
following formula: volume = (length×width×width)/2. Mice were
sacrificed when tumor size in mice treated with vehicle exceeded
600mm3, before the occurrence of physical discomfort (rough hair
coat, lack of grooming activity, or abnormal posture). Tissues (lung,
liver, kidneys, spleen and gastrocnemius muscle) were excised, washed
with saline and weighted for successive ethanol extraction, tumors were
excised, washed with saline, weighted and separated in halves for
ethanol extraction and for histochemical examination by Hematoxylin
& Eosin (H&E) staining.
2.12. Biodistribution assessment for sunitinib, compounds 1 and 3
Tissue samples were homogenized and compounds were extracted
with 1mL of absolute ethanol, following a previously published pro-
cedure [28]. Samples were centrifuged (10,000 g, 4 °C, 10min) and a
fixed volume of the supernatant was evaporated to dryness by a gentle
nitrogen flux. Pellets were then dissolved in the same volume of HPLC
eluent (95% water, 5% MeCN both additioned with 0.1% HCOOH)
containing the internal standard (compound 2), and injected into the
HPLC-MS system for quantification. A Thermo Accela U-HPLC system
equipped with an Accela Open AS autosampler interfaced to a TSQ
Quantum Access Max triple quadrupole mass spectrometer (Thermo,
Milan, Italy) with a heated electrospray ionization (H-ESI) ion source
was employed for data acquisition. Mass spectrometric analyses were
done in positive ion mode. H-ESI interface parameters were set as fol-
lows: probe: middle (D) position; capillary temperature: 270 °C; spray
voltage: 3.5 kV. Nitrogen was used as nebulizing gas at the following
pressure: sheath gas 35 psi; auxiliary gas: 15 arbitrary units (a.u.).
Argon was used as the collision gas at a pressure of approximately 1.5
mtorr (1 torr= 133.3 Pa). For quantitative analysis, the following
multiple parent ion→ product ion transitions were selected: compound
1: m/z = 480.7 [M+2H]2+→ m/z=282.9, 325.7 (tube lens (TL):
95 V; collision energies (CE): 30, 23 eV, respectively); compound 2
(Internal Standard): m/z = 539.8 [M+2H]2+→ m/z=282.9, 325.9,
796.4 (TL: 85 V; CE: 28, 23, 22 eV); compound 3: m/z = 447.9 [M
+3H]3+→ m/z=121.8, 238.5, 282.6 (TL: 65 V; CE: 42, 45, 22 eV);
sunitinib: m/z = 399.3 [M+H]+ → m/z=238.1, 283.1, 326.1 (TL:
62 V; CE: 44, 26, 21 eV). A Phenomenex Synergi Fusion C18 column
(100× 2.1mm; 4 μm particle size) was employed for compound se-
paration following a gradient elution. The flow rate was set at
0.350mLmin−1. Solvent A: water and solvent B: acetonitrile both
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additioned of 0.1% v/v formic acid. HPLC gradient was as follows: t
(0 min): A: 95%; B: 5%; t(8 min): A: 70%; B: 30%; t(10min): A: 70%; B:
30%; t(11min): A: 95%; B: 5% followed by 2min of column re-
conditioning. Retention times were: 6.87min for 1, 6.06min for 2,
4.87 min for 3, and 9.17min for sunitinib. Calibration curves were built
for compounds 1, 3 and sunitinib in the same matrices by spiking stock
solutions of compounds in the control tissue extracts. Linearity was
assessed in the 1000-1 nM concentration range for sunitinib, 1000-
10 nM for 1; 1000-50 nM for 3, employing the IS 2 at the final con-
centration of 100 nM. Correlation coefficient was> 0.99 for all re-
gression lines. Data acquisition and regression analysis were performed
by Thermo Xcalibur software v. 2.1 (Thermo, Milan, Italy).
2.13. TUNEL assay for detection of apoptotic cells
To evaluate apoptosis in tumor specimens, we used terminal deox-
ynucleotidyl transferase (TdT)-mediated dUTP-digoxigenin nick-end
labeling (TUNEL assay) technique, to formalin-fixed paraffin-embedded
sections, using the commercially available TB235 from Promega.
Sections (5–6 μm) mounted on glass slides were deparaffinized, rehy-
drated through graded alcohols to water, treated with 20 μg/mL pro-
teinase K (37 °C, 10min at RT) and then washed in PBS and fixed by
immersing in 4% methanol-free formaldehyde solution for 5min at RT.
TUNEL assay was then performed according to the instructions by the
manufacturer.
2.14. Statistical analysis
Data are shown as mean ± SEM. All experiments were analyzed
using Analysis of Variance (ANOVA) test, and differences among the
various groups were performed using multiple comparison analysis
methods (Tukey tests) using a commercial software (PRISM version 7.0,
GraphPad Software Inc., San Diego, CA, USA). p < 0.05 was con-
sidered significant.
3. Results
3.1. Chemistry and physicochemical characteristics
The three molecular conjugates 1–3 were synthesized by starting
from commercial materials in 14 steps and 10–21% overall yields
(longest linear sequence), according to a modular mixed in-solution/
solid phase synthesis procedure, as previously described [28]. The in
vitro stability of conjugates 1–3 in 80% v/v rat and human plasma was
previously evaluated by HPLC/UV analysis, which showed complete
resistance to plasma degradation during the observed time (8 h) [28].
Merging the low molecular weight, lipophilic and permeable sunitinib
molecule with the hydrophilic cyclic peptidomimetic c(AmpRGD) via
different linkers resulted in “medium-sized” structures 1–3 with new
and diversified properties, as shown in Table 1.
Thus, for example, the presence of the pegylated linker (compounds
2 and 3 vs 1) and the dipeptide presentation (3 vs 1 and 2) increased
the hydrophilic character, as demonstrated by the increasing negative
values of LogDoct,7.4 (distribution coefficient in n-octanol/buffer at pH
7.4). In addition, the presence of diverse basic sites (i.e. the proline Nα
atom in the AmpRGD within 1–3 and the tertiary amine in the linkers of
2 and 3) confer different total charge to these molecules, ranging from
neutral to highly positive, depending on the structure and/or pH
(Table 1; experimental procedure for pKa measurement and related
species distribution curves are detailed in the Supporting Information,
Fig. S1).
3.2. Inhibition of cell adhesion to the αVβ3-integrin ligand vitronectin by
conjugates 1−3
In previous works [24,25], the binding affinity of several c
(AmpRGD)-based cyclopeptides toward selected integrin receptors was
assessed by solid-phase receptor binding assays and, in most cases,
these scaffolds showed one-digit nanomolar IC50 values toward the
αVβ3 integrin receptor and appreciable selectivity as confronted to
other integrin receptors (Table 2). For example, c(AmpRGD)-NH2 4
(used as a reference compound in biological assays in this work), dis-
played IC50 αVβ3 6.1 nM in the competitive displacement of biotiny-
lated vitronectin (VN), a natural ligand of the αVβ3 receptor (entry 1).
Considering the conjugates 1–3, their binding competence toward the
isolated αVβ3 receptor was proven (IC50 1.24–5.1 nM range, entries
2–4), demonstrating that the presence of the sunitinib/linker cargoes
did not compromise their good αVβ3-integrin targeting capability [28].
In the same study, compounds 1–3 were assayed for their ability to
inhibit the adhesion of VN to αVβ3-overexpressing endothelial pro-
genitor cells (EPCs), and the results showed that compounds 1 and 3
strongly inhibited cell adhesion (IC50 ca. 500 nM) even better than the
unconjugated RGD reference (1.8 μM); compound 2, instead, showed an
inferior performance (IC50 ca. 10 μM).
In this study, compounds 1–3 were evaluated for their ability to
inhibit the adhesion to VN of human melanoma cells (M21), whose
abundant αVβ3 expression level (95–98%) was evaluated by flow cy-
tometric analysis (see Fig. S2, Supporting Information). Also, for com-
parison purposes, the unconjugated c(AmpRGD)-NH2 4 was challenged,
toward both M21 cells and αVβ3-lacking cells (namely human prostate
carcinoma cells PC3 and human erythroleukemia cells K562), used as
negative controls. As shown in Fig. 2 and Table 2, a dose-dependent
inhibition on M21 cells was observed for all compounds; in particular,
compound 1 exhibited IC50 slightly better than that obtained for the
unconjugated reference 4. Similarly, double-RGD-presenting compound
3 showed IC50 5.3 μM, while conjugate 2 inhibited cell adhesion at ca.
20 μM. Thus, the inhibition profile of the adhesion to VN of M21 cells
shown by conjugates 1–3 was very similar to that previously observed
using endothelial cells. As expected, compound 4 did not inhibit cell
adhesion to VN in PC3 and K562 cells.
3.3. Cell internalization of sunitinib and conjugates 1–3
The cell internalization of sunitinib and the three different con-
jugates 1–3 was next investigated by using different experimental ap-
proaches. Taking advantage of the intrinsic fluorescent emission of the
sunitinib moiety, we evaluated the uptake after 1 h and 24 h of free
sunitinib at 1 μM concentration and compounds 1–3 (at equimolar su-
nitinib concentration) on M21 cells by cytofluorimetric assay (Fig. 3A
and Fig. S4B). At 24 h we found that sunitinib-associated fluorescence
of M21 cells exposed to sunitinib was higher compared to that of
M21 cells exposed to compounds 1–3. Interestingly, the sunitinib-as-
sociated fluorescence of M21 cells exposed to compound 3 was higher
compared to that of cells treated with compound 1, while the fluores-
cence of M21 cells exposed to compound 2 was negligible. The mea-
surements after 1 h incubation revealed that the internalization of
conjugates 1–3 was sensibly lower than that of sunitinib, and with a
percentage very similar for the three compounds.
To confirm that cell-associated fluorescence was dependent on the
cellular internalization of the drug, single cell-associated fluorescence
was evaluated using the confocal analysis. M21 cells were examined
after 24 h exposure to sunitinib and to the three different compounds
1–3 (1 μM) (see Fig. S4A Supporting Information). We found that the
M21 cell population exposed to sunitinib showed a diffused intra-cy-
toplasmatic green fluorescence signal, corresponding to the internalized
sunitinib, while M21 cell population exposed to compounds 1–3 ex-
pressed lower fluorescence signals. In particular, a faint signal was re-
vealed after treatment with compound 1, a negligible signal was re-
vealed after treatment with compound 2, while treatment with
compound 3 determined a more intense fluorescent signal. These re-
sults were substantially in line with those obtained with the cyto-
fluorimetric analysis. Further, to investigate the selectivity of cell
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internalization, we exposed M21 human melanoma cells, K562 ery-
throleukemia cells and co-cultures to different treatments using suni-
tinib, compound 1 or compound 3 for 24 h. As shown in Fig. 3B and C,
αVβ3-positive and αVβ3-negative cells showed strong sunitinib inter-
nalization, whereas only a percentage of αVβ3-positive cells revealed
internalization after the treatment with conjugates 1 and 3, and, in
agreement with the previous results, compound 3 was internalized
slightly more efficiently. To confirm the selectivity of cell internaliza-
tion of these compounds, we carried out an in vitro competition ex-
periment. The cells were pretreated for 1 h with 10 μM concentration of
c(AmpRGD)-NH2 4, that competes for the integrin binding, and then
incubated with compound 3 (1 μM). The dramatically reduced inter-
nalization of compound 3 that was registered (Fig. 3D) supports the
hypothesis of an integrin-mediated endocytosis of this conjugate. Fi-
nally, the late endosomal-lysosomal localization of sunitinib and con-
jugates 1–3 was evaluated using the anti-Rab7 antibody. As shown in
Fig. 3E, untreated cells showed no signal from Rab7 protein, as ex-
pected in cells not subjected to any endocytic stimulation, while only
free sunitinib colocalizes with Rab7. Compounds 1 and 3 (green
fluorescence signal) were dispersed throughout the cytoplasm and
showed a reduced signal from the Rab7 antibody (red fluorescence
signal) and also a negligible colocalization (orange fluorescence signal)
with Rab7 protein.
3.4. Effects of sunitinib and conjugates 1–3 on ERK1/2 phosphorylation,
invasive phenotype, and proliferation
To evaluate the effect of the different compounds on the cell sig-
naling, we tested ERK1/2 inhibition of phosphorylation in M21 cells
exposed to either compounds 1–3, free sunitinib or c(AmpRGD)-NH2 4
(1 μM) for 1 h (Fig. 4A). It was found that the use of 1 μM sunitinib,
alone or in combination with 4, completely inhibited ERK1/2 phos-
phorylation, while the use of 4 alone had a minimal effect. Treatment
Table 1
Selected physico-chemical properties of compounds 1–3 and sunitinib.
cmp MW (Da) LogDoct,7.4a pKab Charge of prevailing species (pH 7.4)c Charge of prevailing species (pH 6.0)c tPSA (Å2)d
sunitinib 398.5 2.51 9.08 ± 0.05 +1(98%) +1(99.9%) 73.23
1 960.0 −2.03 3.92 ± 0.01 0(88.4%) +1(76.3%) 352.64
6.52 ± 0.01
2 1078.2 −2.56 3.87 ± 0.01 +1(56.6%) +2(94.0%) 354.47
7.25 ± 0.02
8.67 ± 0.01
3 1788.9 −3.02 3.62 ± 0.02 +2(63.6%) +3(70.3%) 642.35
5.53 ± 0.05
7.08 ± 0.02
8.45 ± 0.01
9.50 ± 0.08
a Distribution coefficient in the n-octanol/buffer system, pH 7.4. Reported are means ± SD.
b pKa determined by potentiometric titration at 25 ± 0.5 °C using Sirius T3 instrument. Assays on conpounds 1–3 performed in ionic strength adjusted (ISA) water
0.15M KCl; sunitinib assays performed in ISA water/co-solvent mixture (MeOH 80% ranging between 38% and 52%). Aqueous pKa determined by Yasuda-
Shedlowsky extrapolation.
c Determined by distribution curves (see Fig. S1); percentage of the prevailing species in parenthesis.
d Total polar surface area as predicted by ACD/Labs (I-Lab 2.0).
Table 2
Cell-free and in-cell adhesion assays of c(AmpRGD)-sunitinib conjugates.
cmp Isolated Integrin Receptor IC50(nM)± SDa Cell Adhesion IC50(μM)± SDe
αvβ3(VN) αvβ5(VN) α5β1(FN) EPC(VN)d
(> 87.5% αvβ3;
35–40% α5β1)
M21(VN)d (98% αvβ3; 10%
α5β1; no αvβ5)
PC3(VN)d (no αvβ3; 25%
α5β1; 27% αvβ5)
K562(VN)d (no αvβ3; > 85%
α5β1 no αvβ5)
4 6.1 ± 1.6b 315 ± 137b 151.6 ± 67.6c 1.8 ± 1.3e 6.7 ± 1.2 negligible negligible
1 1.24 ± 0.01e 30.7 ± 17.7e 0.5 ± 0.7e 3.8 ± 1.3
2 5.1 ± 0.6e 101.3 ± 31.3e ∼10e ∼20
3 3.8 ± 0.6e 95.8 ± 46.7e 0.5 ± 0.6e 5.3 ± 0.9
a IC50 values were calculated as the concentration of compound required for 50% inhibition of biotinylated VN or FN binding to human, isolated receptors.
b Ref [25].
c Ref [27].
d IC50 values were calculated as the concentration of compound required for 50% inhibition of cell adhesion to VN. In parenthesis the percentage of aVb3 integrin
expression in EPCs.
e Ref [28].
Fig. 2. Inhibition of M21 cell adhesion to VN in the presence of compounds
1–3, c(AmpRGD)-NH2 4, or sunitinib (2 h). Inhibition of K562 or PC3 cell ad-
hesion to VN in the presence of c(AmpRGD)-NH2 4. The inhibitory activity was
calculated as percentage of cell adhesion to VN in untreated cells and was ex-
pressed as means ± SEM. Experiments were carried out in triplicate.
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with the three conjugates 1–3 at the same concentration strongly re-
duced ERK1/2 phosphorylation, even if to a lower extent than suni-
tinib, with compound 3 inhibiting ERK1/2 phosphorylation better than
compounds 1 and 2. We also found that the treatment with compounds
1–3 compromised M21 cells migratory ability and invasiveness. In
particular, the treatment with compounds 1–3 reduced the ability of
M21 cells to close the wound, better than after the treatment with su-
nitinib, and in a similar way to that obtained after the treatment with
the combination of c(AmpRGD)-NH2 4 and sunitinib (Fig. 4B). In ad-
dition, compounds 1–3 significantly reduced M21 invasiveness through
matrigel-coated filters (Fig. 4C).
To further investigate the role of the different compounds on cell
proliferation, we evaluated M21 growth during 72 h exposure to 1 μM
daily treatments of the different compounds (Fig. 4D). We found that
after 48 h, inhibition of cell proliferation was significantly reduced in
cells exposed to the treatment with conjugates 1–3, c(AmpRGD)-NH2 4,
sunitinib alone or in combination with 4, as compared to untreated
cells. In addition, after 48 h, a certain synergistic inhibitory effect was
observed for the combination treatment, which was annihilated after
72 h. Interestingly, after 72 h, compound 3 was able to significantly
inhibit M21 cells proliferation more efficiently than the combination
treatment and slightly less efficiently than free sunitinib. The inhibition
of growth obtained using the other two conjugates 1 and 2 was com-
parable to that of the combination treatment. Interestingly, we found
that the different treatments induced no cytotoxic effect on M21 via-
bility, evaluated using the trypan blue exclusion assay and cell cycle
analysis (data not shown). To better understand the effect of the com-
pounds on M21 cells growth, we evaluated the levels of caspase 3 ac-
tivation after 72 h exposure to the conjugates 1–3, c(AmpRGD)-NH2 4,
sunitinib alone or in combination with 4.We found that the exposure to
compound 1 and 3 induced the reduction of the entire form of caspase 3
(Fig. S6). Interestingly, as a negative control, αVβ3-integrin negative
PC3 cells exposed to the same treatments revealed a strong inhibition
on cell proliferation only using sunitinib, independently if used alone or
in combination with c(AmpRGD)-NH2 4 (data shown as images from
growing cultures, upper panel in Fig. 4D).
Next, M21 cells were exposed to the various compounds, at 1 μM
concentration, every other day for 6 days in order to verify the possible
escape from drug efficacy. After this treatment, M21 cells were washed
and seeded at low density and allowed to grow for additional 14 days,
using the same treatment schedule. M21 cell clonogenic activity was
determined, by the use of the colony forming assay and expressed as
surviving factor SF. Interestingly, we found that the treatment with c
(AmpRGD)-NH2 4, compound 1 and compound 3, significantly reduced
M21 cell clonogenic activity expressed as SF. Surprisingly, a prolonged
treatment with sunitinib (and also compound 2) significantly increased
M21 cell proliferation, showing a SF in a range of 3 ± 0.5, indicating a
promotion of escaping mechanisms in sunitinib-treated cells but not in
cells treated with compound 3 (Fig. 5A).
Fig. 3. A) Representative images of internalization of conjugates 1–3 or sunitinib as assessed by flow cytometry measurements. Fluorescence intensity (FacScan
FLT1/FITC-A) in M21 cells treated for 24 h with sunitinib or conjugates 1–3 at 1 μM. Percentage intervals indicate fluorescence(FITC-A)-positive cells from three
independent experiments. B) Scatterogram of αVβ3 staining (Cy5-A) and sunitinib (FITC-A) associated green fluorescence of M21 cells, K562 cells and M21:K562 cell
co-cultures upon treatment with sunitinib or conjugated compounds (1 μM) for 24 h. C) Quantification of sunitinib-associated green fluorescence using flow-
cytometry analysis of M21:K562 cell co-cultures treated with sunitinib or conjugated compounds (1 μM) for 24 h. Each column represents the mean values ± SEM of
three experiments (*p < 0.01) in M21 vs K562 cells. D) Representative images of fluorescence confocal analysis of M21 untreated, or exposed to compound 3 at
1 μM for 3 h or to compound 4 at 10 μM for 1 h before exposure to compound 3 for 3 h. After incubation, cells were fixed and processed for fluorescence confocal
imaging. The cell nuclei were stained with DAPI. Scale bar, 20 μm. Experiments were performed at least three times. E) Immunofluorescence analysis of M21 cells
exposed for 24 h to different compounds: anti-Rab7 (red); sunitinib and cAmpRGD-sunitinib conjugates (green). The nuclei were stained with DAPI (blue). Scale bar,
20 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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3.5. In vivo effect of sunitinib, conjugates 1 and 3 on targeted delivery
xenografts and biodistribution studies
Scid beige mice were s.c. injected with 0.7×106 cells in a
PBS:Matrigel 1:1 solution. One week after the injection, when the s.c.
tumors were palpable, mice were randomized into 4 different groups
comprising the control group (treated with PBS), and the groups treated
with sunitinib malate, compound 1 or compound 3. The daily dose of
sunitinib malate was 10mg/kg, while the dose of 1 (20mg/kg) and 3
(40mg/kg) was calculated to have the equimolar concentration of su-
nitinib. Drugs were i.p. administered [40] every day and tumor growth
was measured by the use of a caliper every other day. Mice of each
treatment group did not show any sign of discomfort or weight loss
during the 2-weeks observation time, even though the evaluation of
cardiotoxic and hepato/nephrotoxic effect in treated mice was not
carried out. Compared to untreated mice, tumor growth of mice treated
with sunitinib malate was significantly reduced, reaching almost 22%
reduction in tumor weight at the end of the treatment (Fig. 5B), and a
similar reduction was obtained using conjugate 1. Very interestingly,
treatment with compound 3 reduced the growth of tumors with greater
efficacy, as compared to both untreated mice (55% reduction in tumor
weight), and those treated with sunitinib (Fig. 5B). Histological ex-
amination showed high cellularity in tumor tissues of untreated mice.
Tumor cells are cohesive showing cellular overlap and little pleo-
morphism. Signs of necrosis are present near the periphery of the lesion,
and large and vascular lacunas can be appreciated throughout the le-
sion. Tumor tissue sections of mice treated with sunitinib showed a
reduced cellular staining, reduced vascular lacunas and signs of cellular
damages, highlighted by the swelling of tumor cells that is revealed by
their light stained large cytoplasm and giant nuclei with chromatin
clumping. Cellular damages are more pronounced in the tumors of mice
treated with the RGD-sunitinib conjugates. In particular, tumors treated
with compound 3 showed a high degree of hydropic degeneration,
while sporadic signs of tissue necrosis were present within the lesion
(Fig. 5C). In addition to that we evaluated the presence of signs of in-
tratumoral apoptosis using the TUNEL assay. We observed that the
tumor lesions of mice treated with compound 1 or compound 3 ex-
hibited an enhanced apoptosis, compared with the tumor lesions of
untreated mice and mice treated with sunitinib (Fig. S7).
Finally, we evaluated whether the amount of sunitinib, compounds
1 and 3 in the tumor and in different tissues of the treated mice might
represent a possible driver of compound 3 better efficacy (Fig. 5D). The
Fig. 4. A) Expression of phosphorylated and total ERK and tubulin in M21 cells exposed to compounds 1–3, c(AmpRGD)-NH2 4, or sunitinib for 1 h (1 μM). Upper
panels are representative immunoblots and the lower panels are mean densitometric values ± SEM from three independent experiments of phosphorylated proteins
normalized to their respective total protein. *p < 0.05 in comparison with untreated by ANOVA followed by Newman-Keuls test. B) Upper panels, representative
images of the wound healing assay of M21 melanoma cells grown in the presence of compound 4, sunitinib, their combination or compounds 1–3. Images are taken
immediately after scratching (time 0) and 24 h later (time 24). Scale bar, 1 mm. Lower panels, quantification of wound healing closure. Data are percentages of
wound closure compared to closure in untreated cells and are expressed as mean value ± SEM of at least three independent experiments. *p < 0.05 vs untreated;
**p < 0.05 vs sunitinib. C) Upper panels, representative images of invasiveness of M21 melanoma were grown in the presence of compound 4, sunitinib, their
combination or compounds 1–3 in standard media for 24 h allowed to migrate toward Matrigel-coated filters. Scale bar, 1 mm. Lower panel, quantification of
invasiveness. Data are percentages of migrated cells compared to untreated cells and expressed as mean value ± SEM of at least three independent experiments.
*p < 0.05 vs untreated, **p < 0.05 vs sunitinib. D) Cell proliferation of M21 cells exposed once to compounds 1–3, c(AmpRGD)-NH2 4, or sunitinib for 24 h, 48 h,
and 72 h (1 μM). Upper panel: representative images of M21 cells and PC3 cells exposed once to compounds 1–3, c(AmpRGD)-NH2 4, or sunitinib for 72 h. Lower
panel: Histogram showing the number of living cells (mean value ± SEM) of three independent experiments. *p < 0.05 in comparison with untreated 48 h and 72 h
respectively, **p < 0.05 in comparison with combinatorial treatment.
F. Bianchini et al. Cancer Letters 446 (2019) 25–37
32
mice were sacrificed 24 h after the last i.p. administration. The con-
centration of compounds 1 and 3 in the tumor lesions was significantly
higher than that of sunitinib. Sunitinib distributed in several tissues, in
fact, we found that sunitinib was still present in the lungs, muscles and
above all in the spleen at a higher concentration than compounds 1 or
3. However, compounds 1 and 3 were found at a higher concentration
than sunitinib in the excretory organs, like kidneys and liver. These
results account for the prolonged circulation time of compound 3
compared to compound 1 and sunitinib, and for a selective tissue spe-
cificity and a lower off-organ distribution.
4. Discussion
Advanced melanoma has long been one of the incurable malignant
cancers since the advent of targeted therapy and immune checkpoint
inhibitors. Despite the clinical advantages deriving from the use of
those therapeutic treatments, the insurgence of drug resistance and the
development of severe and life-threatening adverse effects may cause
discontinuation of therapeutic treatment. Hence, the progression-free
survival and overall survival of metastatic melanoma patients remain
critical.
The focus of this work was placed upon three molecular conjugates,
compounds 1–3 (Fig. 1), which are originated by the covalent con-
nection of two “active modules” namely, the known anti-angiogenic
and antitumor sunitinib moiety and the αVβ3-integrin antagonist c
(AmpRGD).
Integrin receptor αVβ3 represents an eligible target for the selective
discrimination of cancer cells due to its overexpression in advanced
melanoma cells and its recognized role in metastatic disease progres-
sion [29,43–45]. The molecular basis for the use of sunitinib in this
preclinical model of advanced melanoma resides in the following ob-
servations. Sunitinib is an antitumor and anti-angiogenic multi-kinase
inhibitor, which exerts its activities on diverse tyrosine kinase-asso-
ciated receptors (RTK) of different growth factors, such as Vascular
Endothelial Growth Factor Receptors 1–3 (VEGFR-1, -2, and -3), Pla-
telet-Derived Growth Factor Receptors alpha and beta (PDGFRα and
PDGFRβ), Fms-like tyrosine kinase-3 (Flt-3), c-KIT and Colony Stimu-
lator Factor-1 Receptor (CSFR-1), whose downstream pathways often
match and combine with melanoma-BRAF-MEK1/2 pathway (Fig. 6).
Sunitinib is clinically approved for the treatment of metastatic renal cell
carcinoma (RCC), imatinib-resistant gastrointestinal stromal tumors
(GISTs), and metastatic pancreatic neuroendocrine tumors [30–33]. It
has been observed that, in patients with advanced melanoma, increased
tumor microvascular density and high level of soluble angiogenic fac-
tors (bFGF-2, VEGF, and IL-8) correlate with worse prognosis and re-
duced progression-free survival [46,47]. Furthermore, VEGF has been
demonstrated to play a role in the pathogenesis, growth, and metastatic
progression of melanoma [48]. Anti-angiogenic agents, including su-
nitinib, have shown some clinical efficacy in the treatment of mela-
noma, with combination therapies (e.g. association with stereotactic
body radiation therapy or therapeutic vaccine) being the most pro-
mising, though problems associated with real long-term effectiveness,
resistance mechanisms insurgence and dosage-dependent toxicity still
hamper their use [32,49–52]. Finally, it has been recently shown that
sunitinib possesses interesting immune enhancer features, thus justi-
fying the opportunity to explore its use in the field of metastatic mel-
anoma [53–55].
Some sunitinib analogue conjugates have been synthesized and
evaluated as either lysozyme-based targeting agents [56,57], imaging
tools [58], or GnRH-receptor directed agents [59], but no covalent and
Fig. 5. A) Inhibition of M21 cell pro-
liferation. M21 cells were grown in the
presence of compounds 1–3, 4, or su-
nitinib (for 6 days). After the incubation
cells were seeded at low density and
colonies were allowed to grow for 2
weeks in standard medium and treated
with compounds 1–3, 4, or sunitinib
every other day. The surviving factor
(SF) was calculated (number of clones
from treated cells)/(treated cells
seeded×Cloning Efficiency). The assay
was carried out in triplicate, and the
mean values ± SEM are shown. Three
independent experiments were per-
formed and representative results from
one experiment were shown. B) Tumor
growth curves and tumor weight
change (mean ± SEM in grams) at the
end of treatment of tumor bearing mice,
i.p. injected daily with vehicle, suni-
tinib or compounds 1 or 3. Arrow in-
dicates the start of the treatment. Data
are expressed as mean value ± SEM
from 6 mice. *p < 0.005 vs vehicle
and **p < 0.005 vs sunitinib. C)
Representative images of tumor tissue
sections of excided in H&E staining
(10X and 40X magnification). Scale bar,
50 μm. D) Evaluation of concentration
at 24 h after the last treatment in dif-
ferent tissues excided from mice treated
with sunitinib (black columns), com-
pound 1 (dark grey columns) or com-
pound 3 (light grey columns). Data re-
present the mean value ± SEM of drug
concentration. *p < 0.005 vs suni-
tinib.
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robust conjugation to a αVβ3-integrin directed ligands has been re-
ported [28].
In this work, the chemical robustness of compounds 1–3 featuring
uncleavable linkers anticipated that both the observed physicochemical
properties (i.e. hydrophilic/lipophilic balance, total charge, solubility,
Table 1), and the subsequent functional behavior in a biological en-
vironment (i.e cell-targeting ability, cell uptake, anti-tumor efficacy)
are associated to these conjugates as intact, unique chemotypes, and not
to their individual, separated components.
Cell adhesion assays performed on both αVβ3-positive M21 cells and
αVβ3-negative PC3 and K562 cells demonstrated that conjugates 1–3 (as
well as unconjugated compound 4) are good antagonists of M21 mel-
anoma cells adhesion to the natural ligand vitronectin. Though the
involvement of other adhesive receptors cannot be completely ruled out
(e.g integrin receptors other than αVβ3), the results in Table 2 and Fig. 2
support the notion that the very good and quite selective binding affi-
nity of the AmpRGD portion toward the αVβ3 receptor is mainly re-
sponsible for the binding competence of these conjugates towards
M21 cells. It is important to highlight that the observation time of the
inhibition of adhesion assay is 2 h-long; thus, even high doses of the
sunitinib portion within conjugates 1–3 are not able to affect the cell
viability, pointing to the conclusion that inhibition of cell adhesion only
relies on RGD antagonism.
Since one of the main interests in therapeutic combination treat-
ments is lowering the dosage of the single drugs, overcoming drug re-
sistance [60], we chose to perform the subsequent experiments using
the 1 μM concentration, which may allow us to highlight possible sy-
nergistic effects. Indeed, the suboptimal reduction of SF (0.8 ± 0.05)
after the treatment with sunitinib malate at 1 μM concentration was
similar to that obtained after the treatment with the combination of
sunitinib and c(AmpRGD)-NH2 4 (Fig. S3).
As mentioned before, the different molecular and physicochemical
properties of the conjugates 1–3 with respect to sunitinib may heavily
affect their cellular internalization. Cytofluorimetric analysis was
exploited to study the internalization, taking advantage from the
fluorescence properties of sunitinib. After a 24 h exposition, the com-
pounds 1–3 were less internalized than sunitinib in M21 cells. However,
we found that, among the three conjugates, compound 3 enters cells
more easily than compound 1, in turn better internalized than com-
pound 2, following a trend similar to that observed for the cell binding
affinities of these compounds. A series of different experiments namely,
i) uptake measurements by cytofluorimetry on αVβ3-positive M21 cells
(Fig. 3A), ii) uptake using co-cultures of αVβ3-positive M21 cells and
αVβ3-negative K562 (Fig. 3B and C), and iii) uptake of compound 3 on
M21 pretreated with excess RGD ligand 4 (Fig. 3D), concurred to em-
phasize the role of integrin αVβ3 in mediating the selective uptake of
compounds 1–3 in M21 cells, as compared to the unselective uptake of
free sunitinib.
To further define possible different behavior in the distribution of
sunitinib and conjugates 1–3 at the subcellular level, the anti-Rab7
antibody was used (Fig. 3E). Sunitinib co-localizes with Rab7 protein,
confirming its preferential accumulation in late endosomal and lyso-
somal vesicles; in fact, sequestration of sunitinib within lysosomal
compartments was reported as a mechanism of tumor resistance to
sunitinib therapy both in vitro and in vivo [61–63]. Conjugates 1–3,
instead, seem to be freely distributed in the cytoplasm.
Though the actual reasons for the absence of lysosomal accumula-
tion of compounds 1–3 are still obscure, it could be conceivable that in
the case of these novel conjugates, whose characteristics as medium-
size, hydrophilic and multiple basic sites-bearing molecules have been
discussed (Table 1) a receptor-mediated internalization process could
be invoked. Once internalized in the acidic subcellular compartments as
endosomes, multiple charged species prevail (Table 1), which could be
responsible for endosomal escape via the known proton sponge effect,
with subsequent dispersion into the cytoplasm [64]. Moreover, we
found out that compounds 1 and 3 can trigger the activation of an
apoptotic program that is not triggered by sunitinib (Fig. S6). Based on
these two observations, compounds 1–3 could represent a viable “al-
ternative” to sunitinib to escape the insurgence of resistance mechan-
isms upon anti-angiogenic and/or anti-tumor treatments.
To evaluate the therapeutic efficacy of conjugates 1–3 at the mole-
cular level, and considering that possible primary targets of the TKI
sunitinib portion are multiple and closely intertwined pathways might
be triggered (vide supra, Fig. 6), we reasoned that evaluation of p-
ERK1/2 inhibition would be a rational first choice as read-out of their
intracellular activity.
It was found that ERK1/2 phosphorylation was completely abol-
ished by 1 h treatment with 1 μM sunitinib malate and partially, but still
efficiently, reduced by the treatment with three conjugates 1–3
(Fig. 4A), while compound 4 was less efficient. The similar behavior
exerted by the compounds 1–3 in inhibiting ERK1/2 phosphorylation at
1 h is in line with the observation of similar amounts of the three
conjugates being internalized in M21 cells after 1 h incubation (Fig.
S4B), even if we cannot exclude that the antagonistic effect of the RGD
portion on integrin αVβ3 can contribute to the inhibition of MAPK
pathway (Fig. 6).
Therefore, we investigated the effect of the different treatments at
the biological level, and we evaluated whether these compounds may
affect melanoma cells motility and invasiveness (Fig. 4C and D). We
found a significant reduction in both cell motility and invasive ability
after 24 h treatment with compounds 1–3 (1 μM) as compared to un-
treated cells. Interestingly, M21 cells motility and invasiveness poten-
tial were slightly affected by sunitinib at the same concentration, while
the combination of c(AmpRGD)-NH2 4 and sunitinib resulted in a sy-
nergic activity in the inhibition of motility and invasiveness, though to
a lesser extent than the covalent conjugates. This behavior seems to
emphasize the superior role of the covalent conjugation of the two
active units as compared to the individual combined components. Mi-
gration and invasion require cell attachment to extracellular proteins
mediated by integrins and other adhesion molecules, and their inhibi-
tion is therefore mainly performed by the RGD portion of the com-
pounds 1–3, that exert their function mostly at the extracellular level.
In fact, compound 2, which is internalized at a lesser extent than 1 and
3 in the 24 h period, resulted to be more active. In addition, to support
Fig. 6. Receptor-mediated signaling in αVβ3-overexpressing melanoma cells.
Activation of cell-surface receptors such as αVβ3 integrin and other tyrosine
kinase growth factor receptors leads to the activation of the RAS/ERK, PI3K/
AKT pathways. The actions of small molecule intracellular antagonists suni-
tinib, extracellular integrin antagonist and those of targeted therapeutic drugs
(vemurafenib, dabrafenib and tramentinib i.e.) are shown. ECM, extracellular
matrix; GR, growth factor; TKR, tyrosine kinase receptor (VEGFR1-3 Vascular
Endothelial growth factor, cKIT/CD117, or PDGFR Platelet derived growth
factor); FAK, focal adhesion kinase; ERK, extracellular signal-regulated kinases.
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the antagonist effect of the conjugates, we investigated the action of
compounds 1–3 and AmpRGD-NH2 4 on cytoskeletal reorganization in
firmly adherent M21 cells. We found that 1 h treatment with 1 μM
conjugates 1–3 causes significant cytoskeletal disorganization (Fig. S5).
This result demonstrates not only that the conjugated compounds are
able to engage the integrin receptors in adherent cells, but also that
their effect (at 1 μM concentration) is more powerful than that of
AmpRGD-NH2 4, in line with the wound healing and invasiveness as-
says.
Having in mind the importance of the issue of dosage reduction, we
explored the anti-proliferative effect on melanoma cells using a low-
concentration, prolonged drug treatment rather than a high-con-
centration, brief treatment (Fig. 4D). We found that low concentrations
(1 μM) of the three conjugates 1–3 significantly reduced the growth of
M21 melanoma cells at 48 h and 72 h compared to untreated cells; in
addition, we found that only compound 3 strongly reduced melanoma
cells growth with comparable efficacy as sunitinib and more effectively
than the combination treatment. Once again, this assessed the super-
iority of the covalent conjugation of the two active modules within 3
over their simple combination. While no acute cytotoxic effect was
found after the treatment, neither any cell cycle arrest was observed, a
possible explanation of the effect of conjugated compounds on cell
proliferation might come from the evaluation of caspase 3 activation.
We found that compounds 1 and 3 induced the reduction of the entire
form of caspase 3. Thus, the induction of apoptosis might explain the
reduction of proliferation after the treatment with the conjugated
compounds. It is important to note that melanoma cell morphology was
deeply changed after treatment with conjugates 1–3, whereas PC3 cells
morphology and proliferation (Fig. 4D upper panel) were not affected,
confirming that inhibition of melanoma cell proliferation is mediated,
also, by αVβ3 integrin recognition.
To investigate the effect of a chronic treatment, the clonogenic ac-
tivity of cells exposed to different treatment was evaluated, and sur-
prisingly we found a significant reduction in M21 SF after treatment
with c(AmpRGD)-NH2 4, similar to that obtained by the treatment with
compound 1, or 3. The treatment with sunitinib, on the other hand,
determined a significant increase in SF, probably due to the instaura-
tion of resistance mechanisms in treated cells. In addition, the combi-
nation of c(AmpRGD)-NH2 4 and sunitinib revealed a SF lower than
that of cells treated with sunitinib malate alone (Fig. 5A).
Finally, to evaluate the effect of the conjugated compounds in vivo,
we treated melanoma tumor-bearing mice with a sub-optimal dose of
sunitinib alone in comparison with compounds 1 and 3 (Fig. 5B). We
opted to use 4-fold decreased dosage (ca. 10mg/kg/d sunitinib
equivalent) [28,42] to better emphasize possible differences between
the tested compounds and evaluate the impact of the in vivo treatment
using low-toxicity dosage. Tumor growth was significantly reduced in
mice treated with either sunitinib alone, compound 1, or compound 3,
as compared to untreated mice. In particular, while the behavior of
sunitinib-treated mice was similar to that observed for mice treated
with conjugate 1, the growth of tumor in mice treated with compound 3
was significantly reduced also compared to sunitinib treatment. Fur-
thermore, in a preliminary, yet incomplete biodistribution assessment
(Fig. 5D), we found that conjugates 1 and 3 were selectively localized
(24 h after the last i.p. injection) in αVβ3-expressing neoplastic lesions
and in the excretory organs, whereas sunitinib was found in every other
analyzed tissue. These very preliminary results confirm the un-
specificity of sunitinib distribution [65] and underline the selective
tumor-targeting ability of the conjugated compounds 1 and 3 as robust
and intelligent sunitinib-targeting vehicles in vivo. The reduction in
tumor growth might partially depend on the cellular hydropic degen-
eration constantly sustained by the treatment with compound 3,
causing a chronic tissue damage and the subsequent activation of
apoptosis (Fig. S7). Despite compounds 1 and 3 were found in the same
amount in the lesion, the more efficient effect of compound 3 on tumor
growth might be attributed to the presence of the two c(AmpRGD)
moieties responsible of a better cellular internalization than compound
1.
5. Conclusions
The molecular conjugates 1–3 derived from the robust, covalent
connection of well-established active components namely, sunitinib and
c(AmpRGD) active units, resulted in interesting tools to investigate the
metastatic melanoma disease. In particular, compound 1 and, even
better, compound 3, drastically reduced the growth of melanoma xe-
nografts on tumor-bearing mice compared to free sunitinib at low
doses, and selectively localized in the tumor tissue.
The selective uptake of these conjugates by melanoma cells was
mainly due to the recognition and binding ability to the αVβ3-integrin,
which is overexpressed in the melanoma cells used in this study; the
observed in vitro and in vivo melanoma cell-selectivity is a good premise
for targeted therapy with consequent dosage reduction and, hopefully,
decreased adverse and toxic effects on healthy tissues, aspects that need
a future investigation.
The molecular conjugates 1–3 have physicochemical properties
different from the constituting units, which consequently dictate a
biological behavior (both in vitro and in vivo) different from the small-
molecule sunitinib. In particular, a decreased aggressiveness in the
M21 cell population was observed under chronic treatment with con-
jugates 1 and 3 as compared to sunitinib. Also, the localization of
conjugates 1–3 in the cytosol as opposed to the compartmentalization
of sunitinib in lysosomes of M21 cells suggests possible overcoming of
another resistance mechanism involving the sunitinib drug.
Due to the multiple biological targets of the sunitinib, it is hard to
strictly define all the targets of conjugates 1–3; however, their action as
antagonists of the αVβ3-integrin and MAPK inhibitors, open the way for
the use of these selective conjugates as drugs able to counteract the
compensatory escape mechanisms that tumor cells establish against
conventional pharmacological treatments.
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